Literature DB >> 29241671

Mkp-1 protects mice against toxin-induced liver damage by promoting the Nrf2 cytoprotective response.

Lin Luo1, Yeru Chen1, Hongyan Wang2, Shengcun Wang3, Kaihua Liu1, Xin Li3, Xiu Jun Wang4, Xiuwen Tang5.   

Abstract

The present study was undertaken to investigate the possible protective effect of mitogen-activated protein kinase phosphatase 1 (Mkp-1) on toxin-induced hepatic injury. Here, we uncovered a positive feedback loop between Mkp-1, a dual threonine/tyrosine phosphatase, and nuclear factor erythroid 2-related factor 2 (Nrf2), a crucial regulator of the defense system in the liver. Mkp-1-/- mice exhibited decreased protein levels of Nrf2, phase II gene products, and reduced glutathione (GSH) in the liver. Induction of detoxifying enzymes by the Nrf2 activator butylated hydroxyanisole (BHA) or sulforaphane, was attenuated in the liver and small intestines of Mkp-1-/- mice, indicating that the Nrf2 signaling pathway is impaired as a result of Mkp-1 deficiency. Mkp-1-/- mice suffered more severe liver injury after a single exposure to hepatotoxin carbon tetrachloride (CCl4) than their wild-type (WT) counterparts. BHA partially rescued the CCl4-induced liver damage in WT mice, but not in Mkp-1-/- mice, suggesting the requirement of Mkp-1 in the activation of Nrf2 signaling against the liver injury. Mechanistically, Mkp-1 upregulated Nrf2 through a direct interaction with the Neh2 domain in the transcription factor, while Nrf2 enhanced the expression of Mkp-1 mRNA by binding to the ARE site at -1719 to -1710bp in the Mkp-1 promoter. Our results reveal novel role of Mkp-1 in the maintenance of redox homeostasis in the liver. Thus, strategies aimed at augmenting Mkp-1 expression may be beneficial in protecting the liver and may provide novel therapeutic approaches to toxin-induced liver injury.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Detoxifying enzymes; Liver; Mitogen-activated protein kinase phosphatase 1; Nuclear factor erythroid 2-related factor 2

Mesh:

Substances:

Year:  2017        PMID: 29241671     DOI: 10.1016/j.freeradbiomed.2017.12.010

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  4 in total

Review 1.  Nrf2 as a potential target for Parkinson's disease therapy.

Authors:  Yingcai Niu; Jing Zhang; Miaoxian Dong
Journal:  J Mol Med (Berl)       Date:  2021-04-12       Impact factor: 4.599

2.  Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.

Authors:  Hongyan Wang; Kaihua Liu; Zhexu Chi; Xihang Zhou; Guoping Ren; Ren Zhou; Yinyan Li; Xiuwen Tang; Xiu Jun Wang
Journal:  Aging (Albany NY)       Date:  2019-12-06       Impact factor: 5.682

Review 3.  NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis.

Authors:  Holly Robertson; Albena T Dinkova-Kostova; John D Hayes
Journal:  Cancers (Basel)       Date:  2020-12-02       Impact factor: 6.639

4.  c-Jun NH2 -Terminal Protein Kinase Phosphorylates the Nrf2-ECH Homology 6 Domain of Nuclear Factor Erythroid 2-Related Factor 2 and Downregulates Cytoprotective Genes in Acetaminophen-Induced Liver Injury in Mice.

Authors:  Yiping Chen; Kaihua Liu; Jingwen Zhang; Yan Hai; Peng Wang; Hongyan Wang; Qiuyan Liu; Catherine C L Wong; Jun Yao; Yang Gao; Yijiao Liao; Xiuwen Tang; Xiu Jun Wang
Journal:  Hepatology       Date:  2020-05       Impact factor: 17.425

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.